The voltage-gated potassium channel KV1.3 as a therapeutic target for venom-derived peptides

2020, September 1 - 12:15
The voltage-gated potassium channel KV1.3 as a therapeutic target for venom-derived peptides


Gabor Tajti, Gyorgy Panyi and their Australian colleagues described the potential application of venom derived KV1.3 voltage-gated ion channel blockers in certain autoimmune diseases, where the possible application is not in mainstream research focus. In their review article they detail the potential applicability of such peptides in inflammatory bowel diseases, neuroinflammatory conditions, such as Alzheimer’s and Parkinson’s diseases, as well as fibrotic liver and kidney diseases. Strategies for facilitating the entry of peptides to the central nervous system is also summarized, given that this is a pre-requisite for the treatment of the aforementioned neuroinflammatory diseases. By systematically reviewing the literature they also report the recently published agents and peptides inhibiting KV1.3 channel, as well as the recent advances in the clinical development of the KV1.3-blocking ShK (peptide isolated from Stichodactyla helianthus-sea anemone) derivatives.

Their paper was published in the Biochemical Pharmacology journal (IF: 4.96).


Dear User!


The University of Debrecen considers the protection of personal data and the information provided to be of paramount importance. We hereby inform you that the University of Debrecen has reviewed its processes and incorporated the requirements of GDPR into his own data management and data protection activities, which entered mandatory on may 25,2018. The personal data of the users has been carefully handled by the University of Debrecen, it complies with the applicable data management regulations.Following the requirements of GDPR, we updated our Privacy Statement, which you can access by clicking on the link below: Privacy Policy.

I have read, understand and agree to terms.